Cancer epigenetics reaches mainstream oncology

By Manuel Rodríguez‐Paredes, Manel Esteller. Nature Medicine, 2011

1,241 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/8ebb352e78c74e6cda1d5c3518d12a989553b68f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

Citations in the corpus

Machine Learning Prediction of Cancer Cell Sensitivity to Drugs Based on Genomic and Chemical Properties (2012, background): “Additionally, epigenetics data could enhance the prediction capabilities of future methods [28].”
SDH mutations establish a hypermethylator phenotype in paraganglioma. (2013, background): “Unlike genetic mutations, DNA methylation is a reversible process and is thus a promising target for drug development (Rodrı́guez-Paredes and Esteller, 2011).”
BRK Targets Dok1 for Ubiquitin-Mediated Proteasomal Degradation to Promote Cell Proliferation and Migration (2014, background): “suppressors in cancer including those pertaining to the regulation of gene expression and post-translational events targeting protein stability [51,52,53,54].”
Cancer Genetics and Epigenetics: Two Sides of the Same Coin? (2012, background): “…the interconnectedness between of these two processes is becoming increasingly apparent with the realization that several epigenetic modifiers are mutated in human cancers (Kasinski and Slack, 2011; Rodrı́guez-Paredes and Esteller, 2011; Schuettengruber et al., 2011;Wilson and Roberts, 2011).”
High-resolution genome-wide DNA methylation maps of mouse primary female dermal fibroblasts and keratinocytes (2014, neutral): “…understanding of CG methylation suggests a diverse role in genome regulation including in the determination of cell type specificity, cellular differentiation, suppression of transposable elements, X-chromosome inactivation, genomic imprinting, DNA-protein interaction and tumerogenesis [9-17].”